Compare Amphastar Pharmaceuticals Inc (AMPH) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs C.H. Robinson Worldwide, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while C.H. Robinson Worldwide, Inc. trades at $193.45 (market cap $22.81B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 27.6× Amphastar Pharmaceuticals Inc's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.3% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CHRW | |
|---|---|---|
Market Cap | $826.08M | $22.81B |
Sector | Health | Industrials |
52-Week High | $30.81 | $200.59 |
52-Week Low | $16.87 | $96.82 |
Enterprise Value | $1.22B | $24.29B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CHRW trades at $193.5, up 0.38% today, with a bullish technical signal from moving averages and a consensus analyst price target of $199.25. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.35 surpassing the $1.23 estimate. The company maintains strong profitability with a 34.84% ROE and recently acquired DeSpir Logistics to enhance high-value cargo capabilities, signaling strategic growth initiatives.
The outlook is positive, supported by earnings momentum and operational efficiency, but risks include a high P/E ratio of 39.17 suggesting premium valuation, exposure to freight market cyclicality, and competitive pressures in the logistics sector. Upside potential hinges on continued execution and industry recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
